Cancer Vaccine Has Strong Response In Young Girls

Girls aged 10 to 14 who received GlaxoSmithKline Plc’s vaccine to prevent infection with the virus that causes cervical cancer had immune responses twice as strong as women 15-25 years old given the vaccine, the company said on Saturday, describing results of a late-stage trial.Glaxo said the first published data from a Phase III trial of its Cervarix vaccine suggest it may provide the strongest and most-prolonged protection if given to girls at very young ages, long before they encounter the sexually transmitted virus."The concentrations of antibodies to the virus were twice as high in the bloodstreams of the young girls,” said Gary Dubin, a senior research official at Glaxo who was the lead author on the study.Antibodies are immune-system proteins that seek out and destroy bacteria and viruses. Vaccines, by introducing the body to snippets of specific bacteria or viruses, train the body to crank out tailor-made antibodies that attack them.Dubin said the trial was not designed to confirm actual effectiveness of the vaccine because few girls in the 10 to 14 age group are yet sexually active. Instead, he said the immune response is the best “surrogate” indicator of the vaccine’s potential ability to protect them from prolonged infection with the virus.Results of the trial were presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C.

MORE ON THIS TOPIC